Lupin Receives International Sustainability Rating System (ISRS) Certification
Mumbai: Pharma major Lupin Limited has announced that the Company has received certification for International Sustainability Rating System (ISRS), 8th edition, from DNV GL, a global service provider for managing risk and helping customers to safely and responsibly improve their business performance. The certification was received after audits were conducted at four of the company's manufacturing facilities located at Mandideep, Tarapur, Ankleshwar and Dabhasa, in India. The results were declared on 6th March 2020.
ISRS is a leading global system to assess, improve and demonstrate the health of an organization's business processes. The ISRS certification helps ensure that business operations are safe and sustainable.
Commenting on the certification, Mr Rajendra B. Chunodkar, President - Manufacturing Operations, Lupin said, "Lupin had first received the ISRS 8th edition certification in 2013 and was then the first pharmaceutical company globally to be recognized by DNV. Maintaining the certification and improving this year's ranking by achieving the highest level for three of our locations endorses the best practices we have adopted in Risk Management, Safety and Sustainability at our manufacturing sites."
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.